إسرائيل - العبرية - Ministry of Health

sanofi israel ltd - imiglucerase - אבקה להכנת תמיסה מרוכזת לעירוי - imiglucerase 400 u/vial - imiglucerase - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia - thrombocytopenia - bone disease - hepatomegaly or splenomegaly.

إسرائيل - العبرية - Ministry of Health

takeda israel ltd - agalsidase alfa - תרכיז להכנת תמיסה לאינפוזיה - agalsidase alfa 1 mg/ml - agalsidase alfa - agalsidase alfa - replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alfa-galactosidase a deficiency).

إسرائيل - العبرية - Ministry of Health

sanofi israel ltd - agalsidase beta - אבקה להכנת תמיסה מרוכזת לעירוי - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

إسرائيل - العبرية - Ministry of Health

sanofi - aventis israel ltd - agalsidase beta 5 mg/ml - powder for concentrate for infusion - agalsidase beta - long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease.

إسرائيل - العبرية - Ministry of Health

sanofi israel ltd - laronidase - תרכיז להכנת תמיסה לאינפוזיה - laronidase 500 units / 5 ml - laronidase - laronidase - aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis i (mps i alfa-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

إسرائيل - العبرية - Ministry of Health

sanofi israel ltd - alglucosidase alfa - אבקה להכנת תרכיז לאינפוזיה - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.

إسرائيل - العبرية - Ministry of Health

medison pharma ltd - galsulfase - תרכיז להכנת תמיסה לאינפוזיה - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

إسرائيل - العبرية - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

إسرائيل - العبرية - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

إسرائيل - العبرية - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 10 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine